For example, in vitro work [87] with human myeloma cells that showed synergy between bortezomib and AVE1642, a humanized anti-IGF-1R mAb, led to a phase I trial (NCT01233895) of AVE1642 alone and with bortezomib in advanced myeloma. This evidence concerns the gene IGF1R and plasma cell myeloma.